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Abstract Little is known about bone mineral density
(BMD) in patients with heroin addiction and subsequent
methadone substitution. The goal of this study was to
compare bone mass density of young HIV-negative women
on long-term methadone treatment to a local group of
young healthy women. Eleven women (aged 20–29) with
previous heroin dependence and current methadone sub-
stitution (20–140 mg, median 60, daily) for 1.5–9 (median
3) years were compared to 30 healthy women (aged
20–28). Participants were examined with dual-energy
X-ray absorptiometry of the lumbar spine (L2–L4), of the
total proximal hip area, and of the femoral neck. Patients
and controls had neither current nor lifetime underweight
condition, had comparable ages at menarche, and did not
differ significantly in current body mass index (21.9 ± 4.0,
respectively, 20.5 ± 1.5 kg/m2) in spite of a largely
unhealthy lifestyle (cigarette, alcohol, and cocaine con-
sumption in patients). Patients’ total-hip parameters were
marginally lower than those of controls (BMD P = 0.054,
T score P = 0.049), whereas the femoral neck and lumbar
spine parameters did not differ significantly between the
two groups. Long-term methadone substitution in HIV-
negative women seems to slightly affect bone mass density.
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Interest in bone mineral density (BMD) in psychiatric
patients has increased in recent years. Some studies have
shown associations between psychiatric illnesses such as
depression, schizophrenia, and personality disorders and
diminished bone density [1–4]. Decreased BMD is known
to occur in young women and men with, e.g., anorexia
nervosa [5–9].
Analgesic therapy with opioids seems to induce the
inhibition of gonadotropin-releasing hormone production,
and chronic hypogonadism is an important cause of oste-
oporosis in both sexes [10]. In addition, opioids may
contribute to increased fracture risk by directly interfering
with bone formation [10–13].
Recent studies have reported an increased risk of
fractures in postmenopausal women using narcotics [14]. A
cross-sectional study also reported reduced BMD in middle-
aged women with different central nervous system–active
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medications and found reduced BMD in subjects with
opioid intake [15]. The decreased BMD in a sample of
young men with past and current heroin abuse and with a
high rate of severe viral infections seemed to be caused by
chronic heroin intake; however, it was hypothesized that
bone mass could be regained by abstinence [16]. The
assumption of low BMD in participants undergoing a
methadone maintenance treatment was supported by
another group. Their study sample consisted of men and
women at different ages and of various ethnic groups who
showed a high percentage of severe viral infections [17]. In
general, previous studies did not discriminate between
patients with and without viral infections.
Severe viral infections such as HIV appear to reduce
BMD [18–21]. Since patients with opioid dependence often
contract HIV infections, we investigated BMD in young
HIV-negative women with previous heroin addiction and
successive methadone substitution treatment during a per-
iod of at least 18 months in order to avoid this confounding
factor. In addition to that, we compared the BMD of this
group to a local age-matched group of healthy young
women under the hypothesis that the patient group would
show a lower BMD compared to controls.
Materials and Methods
Subjects
All 105 Caucasians in the pool of women with heroin
dependence under treatment at the Psychiatric University
Hospital of Zurich were initially contacted. The diagnosis
of heroin dependence was made at this institution accord-
ing to the Diagnostic and Statistical Manual of Mental
Disorders, 4th ed. [22]. Only 47 of these women indicated
interest in participating. Inclusion criteria were (1) age
\30 years, (2) previous heroin consumption of [4 years,
and (3) subsequent methadone substitution for [1 year.
The inclusion criteria reduced the number of potential
participants to 24.
Exclusion criteria were (1) HIV infection (positive HIV
serology at recruitment); (2) current or lifetime under-
weight in adult age (body mass index [BMI] \18 kg/m2),
because underweight can negatively influence bone
metabolism; and (3) pregnancy, because of the altered
hormonal household and radiation exposure of dual-energy
X-ray absorptiometry (DXA).
Finally, a total of 11 women aged 20–29 years were
recruited. Participants completed a questionnaire on soci-
odemographic and anthropometric data, menstrual status,
use of medications, hormonal substitution or contracep-
tives, as well as intake of vitamins, minerals, and calcium
products. The questionnaire also included questions on
participants’ physical activity patterns such as postural and
nonpostural sports and hours of sport per week. The ther-
apeutic setting did not envisage that participants were not
consuming heroin any longer since starting methadone
substitution.
The most important patient data are listed in Table 1.
The duration of heroin consumption ranged from 4 to 15
(median 7) years, and the duration of methadone substi-
tution ranged from 1.5 to 9 (median 3) years.
A total of 30 healthy female medical or psychol-
ogy students without any substance dependence aged
20–28 years were recruited as controls; the other inclusion
and exclusion criteria were the same as in the patient group
(Table 1).
Informed consent was obtained by all participants. The
study was approved by the local ethics committee and
designed in accordance with the ethical guidelines of
Helsinki.
Measurement of BMD by DXA
All patients and controls were examined according to the
following imaging protocol: DXA of the lumbar spine (L2–
L4), of the nondominant total proximal hip, and of the
femoral neck area was performed by means of a Hologic
QDR 4500 R device (Hologic, Waltham, MA). The BMDs
of the lumbar spine (L2–L4), of the total proximal hip area,
and of the femoral neck were expressed in grams per
centimeter squared. Analogous to a previous study [23],
values were also expressed as T and Z scores in absolute
numbers as defined in 1994 by the World Health Organi-
zation (WHO; number of standard deviations below or
above the mean BMD value of young Caucasian women at
peak bone mass and of Caucasian women of the same age,
respectively).
The precision of the DXA measurements and the coef-
ficients of variation at the level of the lumbar spine and the
hip were 1 and 1.5%, respectively. Measurements were
performed on the same scanner for each patient by the
same experienced technician and according to the quality
standards as defined by the International Society for Clin-
ical Densitometry (www.ISCD.org). Similar to a previous
study, T and Z scores were almost identical, differing by
B0.1; therefore, we considered T scores only [23].
Data Analysis
The WHO has provided guidelines for the definition of
osteoporosis, osteopenia, and normal bone density in
postmenopausal women assessed by DXA. In clinical
practice these criteria are commonly used in premeno-
pausal women as well [5, 7]. Thus, we examined our data
using WHO criteria in order to allow comparisons with the
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scientific literature and to provide information on the
clinical severity of bone deficiency in the study sample.
Differences between patients and controls were tested
using t, Mann-Whitney U, or Fisher’s exact test with
Freeman–Halton extension when appropriate [24]. P val-
ues, two-tailed, \0.05 were considered statistically sig-
nificant. Correlation coefficients were determined where
needed. Statistical analyses were performed using SPSS
for Windows, version 12 (SPSS, Inc., Chicago, IL;
1989–2003).
Results
As listed in Table 1, patients and controls did not differ
with regard to age, BMI, age at menarche, and intake of
oral contraceptives. However, women on methadone sub-
stitution had a significantly longer duration of physical
activity per week than controls (P \ 0.001), although their
weight-bearing activity, e.g., jogging, lasted significantly
less. Furthermore, women on methadone substitution were
far heavier smokers than controls (P \ 0.001).
Table 2 shows the parameters characterizing BMD of
patients and controls, according to the DXA measurements
(BMD as well as T score). The total-hip parameters showed
a marginally significant difference between patients and
controls (BMD P = 0.054, T score P = 0.049). The fem-
oral neck and lumbar spine parameters did not differ sig-
nificantly between the two groups. The duration of heroin
and methadone intake showed no correlation with any
BMD parameter.
According to the WHO definitions of osteopenia (DXA
T score B-1.0 SD and[-2.5 SD) and osteoporosis (DXA
T score B-2.5 SD), the DXA examination of the femur/hip
yielded nine patients (82%) with normal bone density and
two (18%) with osteopenia. DXA measurements of the
lumbar spine identified five patients (45%) with normal
bone density, five (45%) with osteopenia, and one (10%)
with osteoporosis. In controls, DXA examination of the
femur yielded 27 women (90%) with normal bone density
and three women (10%) with osteopenia. Measurements of
the lumbar spine identified 22 controls (74%) with normal
bone density, seven (23%) with osteopenia, and one (3%)
with osteoporosis. No statistically significant difference
was found for the distribution of osteopenia and osteopo-
rosis between patients and controls.
Discussion
In this cross-sectional study, the BMD of a small group of
women in their third life decade who had been on
Table 1 Characteristics of patient and control groups
Variable Patients
(n = 11)
Controls
(n = 30)
P
Age (years) 24.5 ± 3.3 22.8 ± 2.1 0.147
BMI (kg/m2) 21.9 ± 4.0 20.5 ± 1.5 0.230
Age at menarche (years) 12.8 ± 2.0 13.3 ± 1.5 0.364
Oral contraceptive use (% of n) 36.4 53.3 0.484
Oral contraceptive intake duration (months) 5.8 ± 4.3 22.7 ± 18.3 0.032
Total physical activity (hours/week) 9.5 ± 6.0 2.8 ± 3.2 \0.001
Weight-bearing activity (hours/week) 0.6 ± 1.3 4.6 ± 3.8 \0.001
Current smoking (% of n) 90.9 40 0.005
Smoking (cigarettes/week) 194.4 ± 91.1 34.5 ± 40.5 \0.001
Current or lifetime alcohol use (% of n) 63.6 23.3 0.026
Current or lifetime hashish use (% of n) 63.6 3.3 \0.001
Current or lifetime cocaine use (% of n) 54.5 0.0 \0.001
Lifetime amenorrhea (% of n) 81.8 0.0 \0.001
Duration of amenorrhea (months) 18.4 ± 15.5 0.0 –
Age at onset of heroin intake (years) 15.1 ± 2.1 – –
Duration of heroin intake (years) 7.5 ± 3.0 0.0 –
Heroin quantity (g/day) 6.8 ± 2.2 0.0 –
Age at onset of methadone intake (years) 21.2 ± 4.1 – –
Duration of methadone intake (years) 3.7 ± 2.9 0.0 –
Daily methadone dose (mg) 63.8 ± 37.7 0.0 –
Data are presented as mean ± SD unless otherwise noted
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methadone substitution for C18 months showed a mar-
ginally significant difference compared to a local age-
matched healthy control group. This difference was evident
at the nondominant total-hip area. Regarding the other
localizations, we found no significant differences, which
confirms our hypothesis only partially.
Women on methadone substitution had several factors
with a putative negative influence of BMD, for which we
expected a severe deficit of BMD in the patient group.
Opiod intake (heroin and methadone) over a long period of
time can induce hypogonadism in young women and sub-
sequently amenorrhea. In the present study, the large
majority of patients were amenorrheic; this endocrinolog-
ical misbalance is a well-known negative factor for BMD
metabolism [25–30]. Furthermore, the patient group had a
high alcohol intake and high nicotine abuse, both factors
having also a negative influence on BMD [31–33]. Some
opioids seem also to compromise bone metabolism [10, 11,
13]. Thus, despite these numerous assumed negative
influences on BMD, the group with methadone substitution
interestingly did not show a severely pathological BMD.
At this point, it is important to consider that different
opioids—heroin and methadone—could exert different
influences on BMD [34]. In this regard, the study of Wil-
czek and Stepan needs to be cited [35]. Here, the authors
investigated BMD and bone metabolism in a small sample
of heroin-addicted young men and women at baseline and
after 1 year of methadone maintenance. Based on their
results, the authors hypothesized that prolonged heroin
addiction could be associated with accelerated bone turn-
over and osteopenia, whereas methadone maintenance
could restore altered bone turnover [35]. Obviously, to test
this hypothesis, longitudinal studies in subjects with heroin
and, separately, methadone intake are required.
Probably because of the absence of HIV infection,
which is very frequent in persons undergoing heroin or
methadone substitution therapy, the results of the present
study are less dramatic than those of Pedrazzoni et al. [16]
and Kim et al. [17], who both reported that opioid intake
causes severe loss of BMD. Pedrazzoni et al. examined the
consequences of chronic heroin intake, without methadone
substitution, on BMD in young men with drug use duration
ranging 1–2 years, but 60% of the sample had serological
evidence of HIV and 80% of HBV infection. The high
presence of severe viral infections may exert an additional
negative effect on bone metabolism [18–21, 36–38]. Kim
et al. also showed a low BMD in women and men of dif-
ferent ethnicities (median age 42 years, range 20–66) on
methadone maintenance treatment over a wide range of
durations (median duration 3 years, range 0–25). In this
heterogeneous sample 28% of the participants were HIV-
positive. The broad age and ethnicity spectrum as well the
presence of HIV infection and the very long heroin intake
weaken the plausibility of comparison with the results of
the present study.
The presence of a local control group of age-matched
women represents, therefore, a strength of the present study
because this healthy group permits a real comparison with
subjects who have very similar life conditions and who live
in the same macroenvironment. On the other hand, it is
conceivable that medicine and psychology students, due to
their health-related education, could lead a particularly
healthy lifestyle, although the distribution of the BMD
parameters showed that at least 10% of the control group
had in some locations at least osteopenia, thus indicating a
relatively broad range of BMD values. Due to the scarce
normative data, BMD values of young healthy women
could well range as in our control group. It must be noted
that there is a paucity of normative data on BMD in general
in young, healthy women. Furthermore, the exclusion of
subjects with a lifetime history of underweight is also a
positive aspect of the study because low BMI can cause
bone loss in healthy young people [39].
Nevertheless, these results have an explorative charac-
ter. Certainly, the very small sample size is a central lim-
itation of the study. Still, the marginal difference found for
the total-hip parameters should not cause a large risk of
overlooking a real difference, if the presence of a lowered
Table 2 BMD in patient and control groups
DXA Patients (n = 11) Controls
(n = 30)
Mean ± SD ta df = 10 P Mean ± SD ta df = 29 P F (1,39) P
Femoral neck BMD 0.83 ± 0.10 – 0.89 ± 0.12 – – 2.084 0.157
T score femoral neck -0.18 ± 0.89 -0.679 0.513 0.34 ± 1.12 1.668 0.106 1.940 0.172
Total-hip BMD 0.90 ± 0.09 – 0.98 ± 0.12 – – 3.961 0.054
T score total hip -0.33 ± 0.71 -1.529 0.157 0.33 ± 0.97 1.835 0.077 4.118 0.049
Lumbar spine BMD 0.97 ± 0.09 – 1.02 ± 0.12 – – 1.149 0.290
T score lumbar spine -0.89 ± 0.80 -3.714 0.004 -0.57 ± 1.06 -2.944 0.006 0.830 0.368
a One-sample t-testing difference from 0
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BMD in at least one location is considered abnormal. Also,
it cannot be excluded that the patient sample could have
other psychiatric pathologies possibly leading to BMD
reduction. Furthermore, the lack of analysis of bone
metabolism markers in blood and/or urine did not permit a
deeper insight into factors influencing BMD. However,
these additional assessments were omitted in order not to
jeopardize the limited compliance of the patient group.
Indeed, subjects with drug addiction often abhor medical
assessments and procedures to a major extent [40].
In conclusion, the findings of this study suggest that
BMD in young women on methadone substitution therapy
and previous heroin use may only marginally differ from
an age- and gender-matched healthy local control group.
The effect of methadone on bone metabolism in young
people is largely unclear and merits thorough investigation.
Despite the severe compliance problems, it is necessary to
carry out long-term follow-up studies in young patients
under methadone treatment. Better knowledge of predictive
and risk factors for BMD in young individuals with
addiction problems would permit an improvement of pre-
vention and treatment.
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